MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
Open accessAbstract
PURPOSE: F]AV-1451), we previously reported that non-demented Parkinson's disease patients show off-target binding in subcortical structures, but no appreciable cortical uptake. However, 59 % of these patients were receiving MAO-B inhibitors at the time of their scan. Here, we retrospectively investigated if MAO-B inhibitors in clinical doses affect flortaucipir binding. PROCEDURES: We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson's disease patients who received MAO-B inhibitors with those who did not. RESULTS: Sixteen of 27 Parkinson's disease patients received MAO-B inhibitors at the time of scan. We found no significant flortaucipir uptake differences between the groups at voxel or regional levels. CONCLUSION: Use of MAO-B inhibitors at pharmaceutical levels did not significantly affect flortaucipir binding. Thus, MAO-B does not appear to be a significant binding target of flortaucipir.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The affinity of [18F]AV-1451 for monoamine oxidase is weak, and MAO inhibitors do not significantly displace its binding in patients with tauopathies.
“Furthermore, affinity of [18F]AV-1451 for monoamine oxidase is weak and the use of MAO-inhibitors does not significantly displace [18F]AV-1451 binding in patients with tauopathies37.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · see citing works
Tau positron emission tomographic imaging in aging and early <scp>A</scp> lzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · see citing works
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615 · see citing works
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · see citing works
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474 · see citing works
Carter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442 · see citing works
Brain monoamine oxidase A inhibition in cigarette smokers
Fowler, J. S., Volkow, N. D., Wang, G., Pappas, N. R., Logan, J., Shea, C. E., Alexoff, D. L., MacGregor, R. R., Schlyer, D. J., Zezulkova, I., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14065 · Cited by 423 · see citing works
Mapping Human Brain Monoamine Oxidase A and B with11C-Labeled Suicide Inactivators and PET
Fowler, J. S., MacGregor, R. R., Wolf, A. P., Arnett, C. D., Dewey, S. L., Schlyer, D. J., Christman, D. R., Logan, J., Smith, M. R., Sachs, H., et al. (1987) · Science · doi:10.1126/science.3099392 · Cited by 389 · see citing works
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357 · see citing works
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain
Ng, K. P., Pascoal, T. A., Mathotaarachchi, S. S., Therriault, J., Kang, M. S., Shin, M., Guiot, M.-C., Guo, Q., Harada, R., Comley, R. A., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0253-y · Cited by 346 · see citing works
Zecca, L., Fariello, R. G., Riederer, P. F., Sulzer, D. L., Gatti, A., & Tampellini, D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03269-0 · Cited by 287 · see citing works
Tau PET in Alzheimer disease and mild cognitive impairment
Cho, H., Choi, J. Y., Hwang, M. S., Lee, J., Kim, Y. J., Lee, H., Lyoo, C. H., Ryu, Y. H., & Lee, M. S. (2016) · Neurology · doi:10.1212/wnl.0000000000002892 · Cited by 267 · see citing works
Monoamine oxidase and cigarette smoking
Fowler, J. S., Logan, J., Wang, G.-J., & Volkow, N. D. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(02)00109-2 · Cited by 251 · see citing works
Zecca, L., Bellei, C., Costi, P., Albertini, A., Monzani, E., Casella, L., Gallorini, M., Bergamaschi, L., Moscatelli, A., Turro, N. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808768105 · Cited by 240 · see citing works
Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies
Tong, J., Meyer, J. H., Furukawa, Y., Boileau, I., Chang, L., Wilson, A. A., & Houle, S. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.19 · Cited by 214 · see citing works
18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
Passamonti, L., Rodríguez, P. V., Hong, Y. T., Allinson, K. S. J., Williamson, D., Borchert, R. J., Sami, S. A. K., Cope, T., Bevan-Jones, W. R., Jones, P. S., et al. (2016) · Brain · doi:10.1093/brain/aww340 · Cited by 207 · see citing works
Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies
Marquié, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Antón‐Fernández, A., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24844 · Cited by 190 · see citing works
[<sup>18</sup>F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, J. L., Lowe, V. J., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Petersen, R. C., Jack, C. R., & Josephs, K. A. (2017) · Movement Disorders · doi:10.1002/mds.26834 · Cited by 159 · see citing works
Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal
Fowler, J. S., Volkow, N. D., Logan, J., Wang, G., Gregor, R. R. M., Schlyer, D. J., Wolf, A. P., Pappas, N. R., Alexoff, D. L., Shea, C. E., et al. (1994) · Synapse · doi:10.1002/syn.890180203 · Cited by 147 · see citing works
Expression of monoamine oxidase B activity in astrocytes of senile plaques
Nakamura, S., Kawamata, T., Akiguchi, I., Kameyama, M., Nakamura, N., & Kimura, H. (1990) · Acta Neuropathologica · doi:10.1007/bf00307697 · Cited by 131 · see citing works
<i>In vivo</i>imaging of neuromelanin in Parkinson’s disease using<sup>18</sup>F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128 · see citing works
Self-citationArnett, C. D., Fowler, J. S., MacGregor, R. R., Schlyer, D. J., Wolf, A. P., Långström, B., & Halldin, C. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb02895.x · Cited by 123 · see citing works
Subcortical <sup>18</sup>F‐AV‐1451 binding patterns in progressive supranuclear palsy
Cho, H., Choi, J. Y., Hwang, M. S., Lee, S. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2017) · Movement Disorders · doi:10.1002/mds.26844 · Cited by 119 · see citing works
Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., Jögi, J., Borroni, E., Schöll, M., Honer, M., et al. (2017) · Movement Disorders · doi:10.1002/mds.26813 · Cited by 118 · see citing works
Ginovart, N., Meyer, J. H., Boovariwala, A., Hussey, D. F., Rabiner, E. A., Houle, S., & Wilson, A. A. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600197 · Cited by 102 · see citing works
Lockhart, S. N., Baker, S. L., Okamura, N., Furukawa, K., Ishiki, A., Furumoto, S., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158460 · Cited by 94 · see citing works
Shcherbinin, S., Schwarz, A. J., Joshi, A. D., Navitsky, M. A., Flitter, M. L., Shankle, W. R., Devous, M. D., & Mintun, M. A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170027 · Cited by 93 · see citing works
Nag, S., Fazio, P., Lehmann, L. E., Kettschau, G., Heinrich, T. K., Thiele, A., Svedberg, M. M., Amini, N., Leesch, S., Catafau, A. M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161083 · Cited by 83 · see citing works
Ikonomovic, M. D., Abrahamson, E. E., Price, J. C., Mathis, C. A., & Klunk, W. E. (2016) · Annals of Neurology · doi:10.1002/ana.24706 · Cited by 81 · see citing works
Melchiorre, M. G., Rosa, M. D., Lamura, G., Torres-Gonzales, F., Lindert, J., Stankūnas, M., Ioannidi‐Kapolou, E., Barros, H., Macassa, G., & Soares, J. J. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146425 · Cited by 63 · see citing works
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy.
Smith, R., Schöll, M., Honer, M., Nilsson, C. F., Englund, E., & Hansson, O. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1650-1 · Cited by 62 · see citing works
Lemoine, L., Saint‐Aubert, L., Nennesmo, I., Gillberg, P., & Nordberg, A. K. (2017) · Scientific Reports · doi:10.1038/srep45496 · Cited by 55 · see citing works
In V ivo cortical tau in Parkinson's disease using 18F‐AV‐1451 positron emission tomography
Hansen, A. K., Damholdt, M. F., Fedorova, T. D., Knudsen, K., Parbo, P., Ismail, R., Østergaard, K., Brooks, D. J., & Borghammer, P. (2017) · Movement Disorders · doi:10.1002/mds.26961 · Cited by 55 · see citing works
Self-citationVermeiren, C., Mercier, J., Viot, D., Mairet‐Coello, G., Hannestad, J. O., Courade, J., Citron, M., & Gillard, M. R. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.07.381 · Cited by 30 · see citing works
18F‐AV‐1451 binds to putamen in multiple system atrophy
Cho, H., Choi, J. Y., Lee, S. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Movement Disorders · doi:10.1002/mds.26857 · Cited by 29 · see citing works
Jensen, S. B., Olsen, A. K., Pedersen, K., & Cumming, P. (2006) · Synapse · doi:10.1002/syn.20258 · Cited by 27 · see citing works
Jensen, S. B., Alstrup, A. K. O., Pedersen, K. T., & Cumming, P. D. (2006) · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A walk through tau therapeutic strategies
Jadhav, S., Ávila, J., Schöll, M., Kovács, G. G., Kövari, E., Škrabana, R., Evans, L., Kontseková, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 286 · see citing works
Schöll, M., Maaß, A., Mattsson, N., Ashton, N. J., Blennow, K., Zetterberg, H., & Jagust, W. J. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.001 · Cited by 227 · see citing works
“Hansen and colleagues (Hansen et al., 2018), however, did not observe significant differences M.”
ResultLeuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0989 · Cited by 222 · see citing works
The development and validation of tau PET tracers: current status and future directions
Okamura, N., Harada, R., Ishiki, A., Kikuchi, A., Nakamura, T., & Kudo, Y. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0290-y · Cited by 183 · see citing works
“However, MAO-B blocking studies in humans demonstrated that flortaucipir did not significantly bind to MAO-B in vivo [87, 88].”
BackgroundAutoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue
Agüero, C., Dhaynaut, M., Normandin, M. D., Amaral, A. C. S., Guehl, N. J., Neelamegam, R., Marquié, M., Johnson, K. A., Fakhri, G. E., Frosch, M. P., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0686-6 · Cited by 173 · see citing works
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
Jie, C. V. M. L., Treyer, V., Schibli, R., & Mu, L. (2021) · Pharmaceuticals · doi:10.3390/ph14020110 · Cited by 111 · see citing works
Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
Lemoine, L., Leuzy, A., Chiotis, K., Rodriguez-Vieitez, E., & Nordberg, A. (2018) · Alzheimer's & Dementia · doi:10.1016/j.dadm.2018.01.007 · Cited by 144 · see citing works
Baker, S. L., Harrison, T. M., Maass, A., La Joie, R., & Jagust, W. J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224113 · Cited by 132 · see citing works
“Age was included in these analyses because possible targets for OFF (iron, MAO-B) are correlated with age.”
BackgroundInfluentialNeuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Kaalund, S. S., Passamonti, L., Allinson, K., Green, O., Hong, Y. T., Fryer, T. D., Arnold, R., et al. (2020) · Brain · doi:10.1093/brain/awaa033 · Cited by 124 · see citing works
Murugan, N., Chiotis, K., Rodriguez-Vieitez, E., Lemoine, L., Ågren, H., & Nordberg, A. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04305-8 · Cited by 82 · see citing works
“Although recent in vitro studies agree on the existence of such a cross-interaction [3, 13, 14, 40], the results of the in vivo studies have been equivocal, probably because of the blocking design used, with the administration of irreversible MAO-B inhibitors [12, 41].”
Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy
Malpetti, M., Passamonti, L., Rittman, T., Jones, P. S., Vázquez Rodríguez, P., Bevan‐Jones, W. R., Hong, Y. T., Fryer, T. D., Aigbirhio, F. I., O'Brien, J. T., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25911 · Cited by 83 · see citing works
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Smith, R. A., Schöll, M., Londos, E., Ohlsson, T. G., & Hansson, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-23041-x · Cited by 75 · see citing works
Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy
Ishiki, A., Harada, R., Kai, H., Sato, N., Totsune, T., Tomita, N., Watanuki, S., Hiraoka, K., Ishikawa, Y., Funaki, Y., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0556-7 · Cited by 61 · see citing works
“Retrospective investigation of [(18)F]AV1451 PET in patients with Parkinson’s disease showed no significant difference between conditions before and after treatment with irreversible MAO-B inhibitors (selegiline and rasagiline) [9].”
PET imaging of tau protein targets: a methodology perspective
Lois, C., González, I., Johnson, K. A., & Price, J. C. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9847-7 · Cited by 63 · see citing works
Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.
Drake, L., Pham, J. M., Desmond, T., Mossine, A. V., Lee, S. J., Kilbourn, M., Koeppe, R., Brooks, A. F., & Scott, P. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00326 · Cited by 45 · see citing works
Neuroimaging of Alzheimer’s disease: focus on amyloid and tau PET
Matsuda, H., Yoko, S., & Sato, N. (2019) · Japanese Journal of Radiology · doi:10.1007/s11604-019-00867-7 · Cited by 40 · see citing works
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00653-x · Cited by 42 · see citing works
Neuroinflammation is highest in areas of disease progression in semantic dementia
Pascual, B., Funk, Q., Zanotti‐Fregonara, P., Cykowski, M. D., Veronese, M., Rockers, E., Bradbury, K., Yu, M., Nakawah, M. O., Román, G. C., et al. (2021) · Brain · doi:10.1093/brain/awab057 · Cited by 41 · see citing works
Imaging Protein Misfolding in the Brain Using β-Sheet Ligands
Harada, R., Okamura, N., Furumoto, S., & Yanai, K. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00585 · Cited by 38 · see citing works
“18F-AV1451 PET in PD patients revealed no significant differences in tracer uptake between patients who received MAO-B inhibitors (selegiline and rasagiline) and those who did not (Hansen et al., 2017), indicating that MAO-B is not an off-target substrate of 18F-AV1451 in the basal ganglia.”
BackgroundHammes, J., Bischof, G. N., Bohn, K. P., Onur, O. A., Schneider, A., Fließbach, K., Hoenig, M. C., Jessen, F., Neumaier, B., Drzezga, A. E., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244061 · Cited by 36 · see citing works
“found that 18F-flortaucipir PET signal cannot be decreased by administration of monoamine oxidase inhibitors (36).”
Background18F-Flortaucipir in TDP-43 associated frontotemporal dementia
Smith, R., Santillo, A. F., Waldö, M. L., Strandberg, O., Berron, D., Vestberg, S., van Westen, D., van Swieten, J., Honer, M., & Hansson, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-42625-9 · Cited by 33 · see citing works
Burnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 29 · see citing works
“443 As for MAO, although contrasting evidence has been reported, 409,410,444-448 recent reports have demonstrated that MAO-A binding is not a significant contributor to the observed PET signal in Alzheimer’s disease and that there is only weak binding of flortaucipir to MAO-B in vitro at micromolar…”
BackgroundComparison of Amyloid β and Tau Spread Models in Alzheimer’s Disease
Kim, H., Lee, P., Seo, S. W., Roh, J. H., Oh, M., Oh, J. S., Oh, S. J., Kim, J. S., & Jeong, Y. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy311 · Cited by 28 · see citing works
“In addition, we expected that using t-statistical maps would minimize the confounding effect of the physiological binding of 18F-THK5351 to MAO.”
ResultInfluentialEvaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy
Varlow, C., & Vasdev, N. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264404 · Cited by 23 · see citing works
Mohammadi, Z., Alizadeh, H., Marton, J., & Cumming, P. D. (2023) · Biomolecules · doi:10.3390/biom13020290 · Cited by 28 · see citing works
Perani, D., Iaccarino, L., Lammertsma, A. A., Windhorst, A. D., Edison, P., Boellaard, R., Hansson, O., Nordberg, A. K., Jacobs, A. H., & IMBI Project (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.004 · Cited by 24 · see citing works
“significantly reduces brain [(18)F]THK5351 uptake [164], whereas [(18)F]flortaucipir uptake seems to be not affected [165], and a recent in vitro study has reported similar nanomolar affinity of [(18)F]flortaucipir to both tau fibrils and MAO-A/MAO-B [166].”
BackgroundWooten, D. W., Ortiz-Terán, L., Zubcevik, N., Zhang, X., Huang, C., Sepulcre, J., Atassi, N., Johnson, K. A., Zafonte, R., & Fakhri, G. E. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.6178 · Cited by 30 · see citing works
“Studies have shown that [(18)F]AV-1451 binds to MAO-A and MAO-B; however, another study has shown MAO-B inhibitors are incapable of blocking [(18)F]AV-1451 uptake.(6,7,42) Additionally,”
BackgroundTau Imaging in Parkinsonism: What Have We Learned So Far?
Whitwell, J. L. (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12584 · Cited by 19 · see citing works
Schaeverbeke, J., Celen, S., Cornelis, J., Ronisz, A., Serdons, K., van Laere, K., Thal, D., Tousseyn, T., Bormans, G., & Vandenberghe, R. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04631-x · Cited by 18 · see citing works
“For example, in Parkinson’s disease, use of MAO-B inhibitors at pharmaceutical levels did not significantly affect [(18)F]AV1451 binding in vivo [47].”
BackgroundThe Role of Tau Imaging in Parkinsonian Disorders
Hammes, J., Drzezga, A., & van Eimeren, T. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0898-3 · Cited by 16 · see citing works
Neuroimaging of Diseases Causing Dementia
Masdeu, J. C. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.003 · Cited by 15 · see citing works
AD molecular: Imaging tau aggregates with positron emissions tomography
Betthauser, T. J. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.007 · Cited by 14 · see citing works
Tau Tangles in Parkinson’s Disease: A 2-Year Follow-Up Flortaucipir PET Study
Hansen, A. K., Parbo, P., Ismail, R., Østergaard, K., Brooks, D. J., & Borghammer, P. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191774 · Cited by 15 · see citing works
Self-citationMonoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation
Wright, J. P., Goodman, J. R., Lin, Y., Lieberman, B. P., Clemens, J., Gomez, L. F., Liang, Q., Hoye, A. T., Pontecorvo, M. J., & Conway, K. A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05822-9 · Cited by 13 · see citing works
Lagarde, J., Olivieri, P., Caillé, F., Gervais, P., Baron, J., Bottlaender, M., & Sarazin, M. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09530-7 · Cited by 12 · see citing works
Josephs, K. A., Tosakulwong, N., Gatto, R. G., Weigand, S. D., Ali, F., Botha, H., Graff‐Radford, J., Machulda, M. M., Savica, R., Schwarz, C. G., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26479 · Cited by 12 · see citing works
“Binding to monoamine oxidase type B (MAO-B) has been raised, but recent evidence did not support MAO-B as a target.(49) It would also not be expected that MAO-B increases over time in subcortical regions of neurodegeneration.”
ResultPascual, B., Funk, Q., Zanotti‐Fregonara, P., Pal, N., Rockers, E., Yu, M., Spann, B., Román, G. C., Schulz, P. E., Karmonik, C., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.225508 · Cited by 10 · see citing works
“Furthermore, unlike other tau PET tracers, 18F-AV-1451 is not appreciably blocked by monoamine oxidase B inhibitors (44), ruling out the possibility that the increased 18F-AV-1451 signal may simply correspond to an increase in monoamine oxidase B induced by the pathologic process (45).”
BackgroundKim, H., Cho, H., Park, S., Jang, H., Ryu, Y., Choi, J., Moon, S., Oh, S., Oh, M., Na, D., et al. (2019) · BMC Neurology · doi:10.1186/s12883-019-1434-z · Cited by 8 · see citing works
“Previous studies suggested that THK5351 has high affinity for MAO-B, as ingestion of MAO-B inhibitor (selegiline) reduced THK5351 uptake [2], whereas MAO-B inhibitor did not block flortaucipir uptake in human brains [13].”
BackgroundChen, Y.-H., Joie, R. L., Pereira, F., Blazhenets, G., Zhu, L., Spina, S., Seeley, W., Heinsen, H., Ushizima, D., Tosun, D., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-02983-x · Cited by 9 · see citing works
Zhang, W., Xu, S., Yu, H., Li, X., Jin, Z., Li, Y., & He, Z. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01566-4 · Cited by 8 · see citing works
Kim, M. H., Jung, W. J., Jeong, H. J., Lee, K., Kil, H. S., Chung, W.-S., Nam, K. R., Lee, Y. J., Lee, K. C., Lim, S. M., et al. (2022) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12532 · Cited by 8 · see citing works
Preclinical Evaluation of Novel PET Probes for Dementia
Cools, R., Kerkhofs, K., Leitao, R. C. F., & Bormans, G. M. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.03.004 · Cited by 8 · see citing works
Molecular Imaging of Extrapyramidal Movement Disorders with Dementia: The 4R Tauopathies
Frey, K. (2021) · Seminars in nuclear medicine · doi:10.1053/j.semnuclmed.2020.12.003 · Cited by 6 · see citing works
Matsuda, H., & Yamao, T. (2023) · Fukushima Journal of Medical Science · doi:10.5387/fms.2023-08 · Cited by 5 · see citing works
Ye, R., Kivisäkk, P., Goodheart, A. E., Fatima, H. A., Peterec, E., Thibault, E. G., Properzi, M. J., Johnson, K. A., Arnold, S. E., & Gomperts, S. N. (2025) · Movement Disorders · doi:10.1002/mds.30238 · Cited by 5 · see citing works
“45,46 In addition, putative off-target binding to monoamine oxidase type B (MAO-B) and Monoamine oxidase type A (MAO-A) appears to be low, 47,48 and off-target binding to neuromelanin does not impact neocortical uptake.”
Tau positron emission tomography in tauopathies: A narrative review
Lee, H., Gu, Y., Seo, S. W., & Moon, S. H. (2023) · Precision and Future Medicine · doi:10.23838/pfm.2023.00016 · Cited by 3 · see citing works
Joint EANM/SNMMI recommendations on the use of Tau PET imaging in Alzheimer's disease
Brendel, M., Kuo, P. H., Brumberg, J., Doré, V., Drzezga, A. E., Garibotto, V., Leuzy, A., Mathoux, G., Meyer, P. T., Moscoso, A., et al. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100214 · Cited by 3 · see citing works
Tauopathy in the APP swe / PS1 ΔE9 mouse model of familial Alzheimer’s diseasePreprint
Metaxas, A., Thygesen, C., Kempf, S. J., Anzalone, M., Vaitheeswaran, R., Petersen, S., Landau, A. M., Audrain, H., Teeling, J. L., Darvesh, S., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/405647 · Cited by 2 · see citing works
Self-citationMcNamara, C. C., Biju, A. P., Hipolito, E., Nguyen, N.-H.-T., Liang, C., & Mukherjee, J. (2026) · Journal of labelled compounds & radiopharmaceuticals · doi:10.1002/jlcr.70003 · Cited by 1 · see citing works
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12486836
Imaging Markers of Amyloid and Tau in Alzheimer Disease
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_20
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12872198
- Authors
- Hansen, A. K., Brooks, D. J., & Borghammer, P.
- Affiliations
- Aarhus University (DK)
- Corresponding author
- Hansen, Allan K.
- Venue
- Molecular Imaging and Biology
- Published
- 2017-11-10
- Volume
- 20
- Issue
- 3
- Pages
- 356-360
- ISSN
- 1536-1632 (ISSN-L)
- 1860-2002
- OpenAlex
- W2767466667
- Cited by
- 51
- References
- 37
- Citations by year
- 2026: 3 · 2025: 2 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 16 · 2018: 10 · 2017: 1
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- green
- pure.au.dk
- Licence
- Locations
- Molecular Imaging and Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lundbeckfonden
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- flortaucipir, monoamine oxidase B inhibitors, Parkinson's disease, off-target binding, amyloid imaging, standardized uptake value, drug interference
- MeSH terms
- Aged, Carbolines, Female, Humans, Male, Monoamine Oxidase, Monoamine Oxidase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
